… , and the multidrug resistance of breast cancer cells [25]. … survival (RFS) and differential
expression analyses. The expression … this effect was the direct result of proteasome inhibition. To …

… ) is a cancer of terminally differentiated plasma cells and represents … proteasome inhibitors,
Zhu at al. identified 37 genes that enhance bortezomib activity in the multiple myeloma cells …

… on the proteasome. Accordingly, we utilized the proteasome inhibitor Bortezomib which is
applied … Finally, differential expression analysis between the different cell lines and clones was …

… of confounders on cell viability for MCF7 and HCC38 breast cancer cell lines … and a
proteasome inhibitor (bortezomib). Variance component analysis demonstrated that variations in cell …

… plasma cells, the terminally differentiated effector cells of … bortezomib downregulates HK2
expression in MM cells provides evidence for a functional link between proteasome inhibition …

… -approved proteasome inhibitors (bortezomib, carfilzomib, … differentiated cell lines HepG2
and HuH7 than for JHH6, as already reported in the literature for another proteasome inhibitor […

… success of the FDA approved proteasome inhibitors (PIs) bortezomib (Velcade, Btz), carfilzomib
… Based on the differential expression pattern of proteasome catalytic subunits in H727 as …

… Bortezomib (Velcade), a proteasome inhibitor … proteasome subunits expression in bortezomib
efficiency, we investigated whether OS cells display differential sensitivities to bortezomib …

… p53 protein stabilized via proteasome inhibition to perform similar … Treating mice with the
proteasome inhibitor bortezomib … : differentiated cells in the villi, rapidly proliferating cells in the …

… Our ndings further support the use of Bortezomib for the treatment … Differential bortezomib
sensitivity in head and neck cancer lines … in human mesothelioma and breast cancer cell lines. …